Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

3.320 +0.060 (+1.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fulcrum Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024. 
Via Talk Markets
Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views
Via Benzinga
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Dow Surges Over 100 Points; ModivCare Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Surges 3%; Kroger Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The company consider suspending the program. 
Via Benzinga
US Stocks Mixed; Producer Prices Increase In August
Via Benzinga
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in... 
Via Benzinga
Earnings Preview: Fulcrum Therapeutics
Via Benzinga
Preview: Fulcrum Therapeutics's Earnings
Via Benzinga
The Latest Analyst Ratings for Fulcrum Therapeutics
Via Benzinga
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024
FULC stock results show that Fulcrum Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. 
Via Benzinga
MicroMarvet - Fulcrum Therapeutics - Confusing Projections And Recommendation
Revenue is estimated to be down 63.40% this year and down another 19.80% next year. Earnings are projected to increase 32.80% this year but be down 9.80% next year. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
Why Splunk Are Trading Higher By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Electriq Power Holdings, Inc. (NYSE: ELIQ) shares jumped 130.3% to $3.3847. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.